The question many Market Authorisation Holders (MAH) are asking themselves at the moment is how they can use artificial intelligence in pharmacovigilance literature review.
Read the case study to find out more about how with DialogML and Drug Safety Triager, GSK will benefit from the opportunity to further improve the efficiency of its literature review process.
